Rebamipide for GERD
Rebamipide is not recommended as a standard treatment for GERD based on current evidence-based guidelines, which establish PPIs as first-line therapy; however, rebamipide may serve as an adjunctive agent to reduce symptom recurrence during PPI maintenance therapy in select patients.
Guideline-Based Standard of Care
The 2022 AGA Clinical Practice Update establishes a clear treatment algorithm for GERD that does not include rebamipide 1:
- First-line therapy: 4-8 week trial of single-dose PPI for patients with typical reflux symptoms (heartburn, regurgitation) without alarm symptoms
- Dose escalation: If inadequate response, increase to twice-daily PPI or switch to a more effective acid suppressive agent
- Adjunctive pharmacotherapy should be personalized to GERD phenotype and includes:
- Alginate antacids for breakthrough symptoms
- Nighttime H2 receptor antagonists for nocturnal symptoms
- Baclofen for regurgitation or belch-predominant symptoms
- Prokinetics for coexistent gastroparesis
Rebamipide is notably absent from these evidence-based recommendations 1.
Evidence for Rebamipide in GERD
Potential Benefits (Limited Evidence)
Rebamipide may have a role as an add-on therapy rather than monotherapy:
Reduced symptom recurrence: One randomized trial showed combination therapy with lansoprazole 15 mg plus rebamipide 300 mg daily reduced symptom recurrence to 20% versus 52.4% with lansoprazole alone over 12 months (P < 0.05) 2. This represents the strongest clinical evidence for rebamipide in GERD.
Mechanism: Rebamipide enhances mucosal protection through prostaglandin synthesis, free radical scavenging, and increased mucin production 3, 4. Animal studies suggest it may enhance tight junction protein expression when combined with PPIs 5.
Critical Limitations
PPI-refractory NERD: A prospective randomized placebo-controlled trial found rebamipide did not effectively control reflux symptoms in patients with non-erosive reflux disease whose symptoms were refractory to PPI therapy 6. QUEST and GSRS scores did not differ between rebamipide and placebo groups.
Not FDA-approved for GERD: The FDA drug label information provided relates to ramipril (an ACE inhibitor), not rebamipide, indicating rebamipide lacks FDA approval for GERD treatment in the United States 7.
Regional use only: Rebamipide is primarily used in Southeast Asia, Russia, and Japan—not in Western countries where the AGA guidelines apply 4.
Clinical Algorithm
For newly diagnosed GERD:
- Start with PPI monotherapy (single daily dose for 4-8 weeks) 1
- Do NOT use rebamipide as first-line therapy
- Assess response and titrate PPI as per guidelines
For patients on chronic PPI maintenance with recurrent symptoms:
- Confirm GERD diagnosis with objective testing if not previously done 1
- Optimize PPI dosing (consider twice-daily if needed)
- Consider rebamipide 100 mg three times daily as adjunctive therapy only if:
- Patient has mild erosive esophagitis (LA grade A or B)
- Symptoms recur during standard-dose PPI maintenance
- Access to rebamipide is available (not FDA-approved in US)
For PPI-refractory symptoms:
- Do NOT add rebamipide—it has proven ineffective in this population 6
- Instead, perform pH-impedance monitoring on PPI to determine mechanism 1
- Consider neuromodulation, behavioral therapy, or anti-reflux procedures based on findings 1
Safety Considerations
Rebamipide demonstrates a favorable safety profile with mild adverse events including dyspepsia, somnolence, dry mouth, and edema occurring within 2-9 days 8. However, this does not justify its use over evidence-based therapies.
Critical Pitfall
The most important caveat: Do not substitute rebamipide for PPI therapy or use it as monotherapy for GERD. The evidence supporting PPIs is robust from multiple high-quality trials, while rebamipide evidence is limited to small Asian studies with conflicting results. The 2022 AGA guidelines, representing the highest quality evidence synthesis, do not support rebamipide use 1.